Ketamine, a painkiller used by the army, does not impair tolerance to blood loss

October 21, 2020

A low dose of ketamine, administered intravenously, does not alter a healthy human's tolerance to blood loss. In other words, if someone was given ketamine to kill pain associated with a battlefield injury, they would be able to tolerate blood loss just as well as someone who did not received this pain killer.

That's according to new research published today in The Journal of Physiology.

Medics in the US Army give ketamine for pain relief associated with a battlefield injury. Such injuries are often accompanied with significant blood loss. Ketamine is also now being used by civilian medical personnel, such as emergency medical personnel, for pain control after a traumatic accident. However, little is known whether ketamine alters the ability of an individual to tolerate major blood loss following an injury.

In this study, funded by the US Army, the research found that the dose of ketamine administered on the battlefield does not alter a person's ability to tolerate a simulation of major blood loss. This finding was identified in both healthy men and women that possess similar physical characteristics of US Army personnel.

This study, conducted on conscious humans, provides experimental evidence that giving a low dose of ketamine (20 mg intravenous) does not alter the tolerance to progressive blood loss. These findings will assist medical personnel in choosing the ideal pain medication for a serious injury with accompanying blood loss, particularly on the battlefield.

The study involved 30 healthy volunteers, 15 male and 15 female adults, having physical characteristics of US Soldiers completed the study. Each volunteer participated in two experimental trials, in random order, where they received either saline (placebo) or ketamine (pain medication) immediately before the onset of a simulated blood loss procedure called lower-body negative pressure.

While lying on their back, each volunteer was sealed in a box-like chamber from the waist down and progressively increased levels of suction were applied to the lower body. This suction transfers blood from the upper body (chest and head areas) to the lower limbs simulating gradual blood loss.

Tolerance capacity of this simulation of blood loss was determined by the time it takes to reach well-recognized physiological symptoms of impending fainting (pre-syncope).

The participants, regardless of body size, received the identical amount of ketamine i.e, 20 mg intravenous racemic ketamine hydrochloride. This fixed dose of ketamine is consistent with the guidelines from the US Army's Committee on Tactical Combat Casualty Care.

The obtained findings may be dissimilar if body-mass specific dosage of ketamine was given. Also, the participants were healthy, relatively young, weighed a minimum of 143 lbs, and were not obese. Thus, the obtained findings should not be applied to other populations, especially to people with underlying diseases.

Craig Crandall, an author on the study, commented:

"Ketamine is one of four pain medications recommended for use in the battlefield after a serious injury. Further studies are needed to investigate if the use of these other medications - fentanyl, morphine, and sufentanil - alters tolerance to simulated blood loss. Further research is also warranted to investigate the effects of different dosages of ketamine in these experimental conditions and in a more varied population."
-end-


The Physiological Society

Related Ketamine Articles from Brightsurf:

Ketamine, a painkiller used by the army, does not impair tolerance to blood loss
A low dose of ketamine, administered intravenously, does not alter a healthy human's tolerance to blood loss.

New study finds antidepressant drug effective in treating "lazy eye" in adults
In a new study, published in Current Biology, researchers from the University of California, Irvine School of Medicine reveal how subanesthetic ketamine, which is used for pain management and as an antidepressant in humans, is effective in treating adult amblyopia, a brain disorder commonly known as ''lazy eye.''

Depression risk detected by measuring heart rate changes
For the first time doctors have shown that measuring changes in 24-hour heart rate can reliably indicate whether or not someone is depressed.

High doses of ketamine can temporarily switch off the brain, say researchers
Researchers have identified two brain phenomena that may explain some of the side-effects of ketamine.

New study shows how ketamine combats depression
The anaesthetic drug ketamine has been shown, in low doses, to have a rapid effect on difficult-to-treat depression.

JNK protein triggers nerve cells to withdraw their synapses when stressed
New study from Eleanor Coffey's lab at Turku Bioscience Center in Finland identifies that the JNK protein triggers nerve cells to withdraw their synapses when stressed.

Ketamine use is underreported -- likely due to unknown exposure -- among EDM partygoers
Nearly 37% of electronic dance music (EDM) party attendees test positive for ketamine use when samples of their hair are tested -- despite only 14.6% disclosing that they have used the drug in the past year.

Common genetic link between autism and Tourette's impairs brain communication
Scientists have discovered how a genetic alteration that increases the risk of developing Autism and Tourette's impacts on the brain.

Single dose of ketamine plus talk therapy may reduce alcohol use
A single infusion of ketamine plus behavioral therapy helped alcohol-dependent individuals reduce their drinking, a new study finds.

One shot of ketamine could reduce problem drinking
A one-off dose of ketamine could help heavy drinkers reduce their alcohol intake, finds a new UCL experimental study published in Nature Communications.

Read More: Ketamine News and Ketamine Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.